

FREQUENCY AND GENOMIC ASPECTS OF INTRINSIC RESISTANCE TO VISMODEGIB IN LOCALLY ADVANCED BASAL CELL CARCINOMA

Yurchenko et al.

SUPPLEMENTAL MATERIALS

SUPPLEMENTAL TABLES

Supplemental Table 1: Patients characteristics

Demographic and clinical characteristics	Total (N=148)
Age	74 [61 - 84.5]
Sex	
Female	66 (45%)
Male	82 (55%)
Gorlin	23 (16%)
Previous chemotherapy	10 (7%)
Previous radiotherapy	23 (16%)

Data are median [IQR] or n (%)

Age and previous therapy: there was 1 missing data point

Supplemental Table 2. Clinical criteria of disease status after treatment.

Type	Tumor growth	Tumor shrinkage
IR	> 20%	-
AR	-	30% followed by regrowth
SD	< 30%	< 30%
CR	-	remission
PR	-	> 30%

Supplemental Table 3. Clinical characteristics of the IR-BCC samples used for the genomic study.

Patient	NB020	NB021	NB022	NB023	SG005
Age at vismo initiation	65	87	90	45	81
Gender	Male	Male	Male	Male	Female
Gorlin	No	No	No	No	No
Localisation	internal right canthus	left ear	nose	forehead	forehead nose left and right eye lids
Prior RXT	No	No	No	Yes, 27 years before HPI treatment	Yes, 18 years before HPI treatment
Prior Chemo	Yes, 1 month before HPI treatment	No	No	Yes, 1 year before HPI treatment	No
Time of progression to advanced state	6 years	5 years	4 years	26 years	8 years
Duration of TT with Vismodegib	1 year	8 months	4 months	2 months	4 months + 2 months with Sonidegib
Histological classification	Basosquamous	Morpheaform	Basosqua mous	Basosquamo us/ undifferentia ted	Basosqua mous/ dedifferent iated

Supplemental Table 4. Risk factors of intrinsic and acquired resistance

Patients characteristics	Association with IR		Association with AR	
	SHR [95%CI]	p-value	SHR [95%CI]	p-value
Age > 70	1.00 [0.27 – 3.68]	1	0.80 [0.28 – 2.28]	0.68
Female gender	0.15 [0.02 – 1.19]	0.07	2.33 [0.79 – 6.9]	0.13
Gorlin syndrom	ND*	0.19	0.87 [0.20 - 3.66]	0.84
Previous chemotherapy	8.85 [2.25 – 34.8]	0.002	1.01 [0.15 – 7.06]	0.99
Previous radiotherapy	0.68 [0.08 – 5.49]	0.72	0.41 [0.05 – 3.3]	0.41

SHR: Sub-Hazard distribution Ratio; IR: intrinsic resistance; AR: Acquired resistance

*since no IR was observed in the Gorlin group, SHR cannot be calculated. The reported p-value corresponds to Gray test for comparison of cumulative incidences